Athira Pharma Inc reports results for the quarter ended September 30 - Earnings Summary

Athira Pharma Inc reported a quarterly adjusted loss of $1.68 per share for the quarter ended September 30, exceeding last year's loss of $7.50 per share. Analysts had expected a loss of $1.22 per share. The company reported zero revenue and a quarterly loss of $6.61 million. Athira's shares fell by 3.1% this quarter and 31.7% year-to-date. The average analyst rating is "hold" with no strong buy recommendations. The earnings estimates have risen by 11.6% in the last three months, with no revisions in the last 30 days.

Athira Pharma Reports Reduced Losses Amid Cost Cuts

Athira Pharma, Inc. reported its Q3 earnings, showing a reduced net loss of $6.6 million, down from $28.7 million a year prior. This improvement is due to significant cuts in operating expenses, particularly in research and development, which decreased to $2.8 million from $17.9 million. Despite these gains, the company faces challenges, including the need for additional funding. Athira's management is focused on advancing its drug pipeline, especially ATH-1105, while seeking strategic transactions to enhance its financial stability.

notice_summary_ytd.revenue_title

Athira Pharma | 8-K: FY2025 Q3 Revenue: USD 0

Athira Pharma reports third quarter loss and reduced R&D expenses

Athira Pharma Inc. reported a net loss of $6.6 million for Q3 2025, significantly reduced from $28.7 million in Q3 2024. The company’s cash balance decreased to $25.2 million, while net cash used in operations fell to $26.3 million from $71.2 million year-over-year. R&D expenses dropped to $2.8 million from $17.9 million, and general administrative expenses were $4.1 million, down from $7.6 million. Athira is exploring strategic alternatives and presented positive Phase 1 trial results for ATH-1105.